Change history
03 June 2019
The original version of this article contained a mistake in one of the author names. Cem Irili should have been Cem Mirili.
03 June 2019
The original version of this article contained a mistake in one of the author names. Cem Irili should have been Cem Mirili.
References
Gualberto A (2012) Brentuximab vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin In Drugs 21:205–216
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30:2183–2189
Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J (2013) Brentuximab vedotin in refractoy CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a named patient programme at a single UK center. Haematologica 98:611–614
Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, Corradini P, Spina M, Brusamolino E, Gianni AM, Santoro A, Botto B, Derenzini E, Pellegrini C, Argnani L (2013) brentuximab vedotin İN relapsed or refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 98:1232–1236
Gopal AK, Chen R, Smith SE, Ansell AM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X, Sievers EL, Younes A (2015) Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 125:1236–1243
Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Goker H, Baslar Z, Ferhanoglu B (2015) Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol 94:415–420
Conflict of Interest
The authors declare that they have no conflict of interest.
Informed Consent
Informed consent has been taken from patient and his relatives.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paydas, S., Ogul, A., Irili, C. et al. Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma. Ann Hematol 95, 145–146 (2016). https://doi.org/10.1007/s00277-015-2493-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-015-2493-x